Opportunity Information: Apply for PAR 19 269
The grant opportunity titled "Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)" (Funding Opportunity Number PAR-19-269) is a National Institutes of Health (NIH) cooperative agreement program aimed at pushing Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) research forward using modern artificial intelligence methods. The central idea is to support teams that can build and apply AI, machine learning, and deep learning approaches (grouped under the term "cognitive systems") to analyze existing, community-accessible datasets and, through that analysis, identify gene mutations or genetic variants that either increase risk for AD/ADRD, contribute to disease mechanisms, or potentially protect against developing these conditions. In practical terms, the FOA is looking for computational approaches that can extract meaningful signals from complex, high-dimensional biological data and connect those signals to disease risk, resilience, and underlying biology.
A key emphasis in the announcement is the use of multiple data types that are already available to the broader research community. That includes genetic and genomic data (such as variant data and other genome-scale measurements) as well as biomarker and phenotypic information, which could span molecular biomarkers, clinical traits, and other measurable characteristics tied to AD/ADRD. The expectation is that applicants will not simply apply generic models, but will propose thoughtful analytic strategies capable of handling the scale and complexity of these datasets, finding patterns that traditional analysis might miss, and producing results that are biologically interpretable and useful for the field. The ultimate deliverable implied by the FOA is stronger evidence about which specific variants matter for disease risk or protection and how those variants may relate to measurable biological or clinical features.
The funding mechanism is a U01 cooperative agreement, which typically indicates substantial scientific involvement or coordination with NIH staff compared with a standard investigator-initiated grant. While the exact award ceiling and number of expected awards are not listed in the provided text, the cooperative agreement format generally signals that NIH anticipates active collaboration, shared milestones, and a structured approach to project management. The activity category is Health, and the CFDA number associated with the program is 93.866. The FOA is explicitly labeled "Clinical Trial Not Allowed," meaning the supported work should focus on computational and analytic research rather than prospective interventional studies that meet the NIH definition of a clinical trial.
Eligibility is broad and includes many organization types across government, academia, nonprofit, and industry. Eligible applicants include state, county, city or township governments, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding higher education institutions under those categories); for-profit organizations other than small businesses; small businesses; and other entities. The FOA also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations). This wide eligibility signals an intent to attract multidisciplinary teams with strengths in AI/ML, genomics, and neurodegenerative disease research, including groups that may bring unique populations, computational infrastructure, or methodological expertise.
From a timeline standpoint, the FOA was created on 2019-05-06, and the original closing date listed is 2022-09-07. Even though that specific date may reflect an earlier submission cycle, the description captures the program's core goals: leveraging AI-driven "cognitive systems" to discover and prioritize AD/ADRD-related genetic variants by integrating and analyzing existing genetic, genomic, biomarker, and phenotypic datasets.Apply for PAR 19 269
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2019-05-06.
- Applicants must submit their applications by 2022-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the official title of this grant opportunity?
The opportunity is titled "Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)".
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR-19-269.
Which federal agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity.
What type of funding mechanism is used?
The mechanism is a U01 cooperative agreement, which generally indicates NIH expects substantial scientific involvement or coordination with NIH staff compared with a typical investigator-initiated grant.
What does a "cooperative agreement" imply for how the project will run?
Based on the description provided, the U01 format typically signals active collaboration with NIH, along with shared milestones and a more structured approach to project management than standard grants.
What is the main purpose of this FOA?
The FOA aims to push Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) research forward by supporting teams that build and apply modern artificial intelligence (AI) methods (including machine learning and deep learning, collectively referred to here as "cognitive systems") to analyze existing datasets and identify genetic factors linked to AD/ADRD.
What kinds of discoveries is NIH looking for through this program?
The goal is to identify gene mutations or genetic variants that may:
- Increase risk for AD/ADRD
- Contribute to disease mechanisms
- Potentially protect against developing AD/ADRD (resilience/protection)
What does "cognitive systems" mean in this funding opportunity?
In this FOA, "cognitive systems" refers to computational approaches using AI, machine learning, and deep learning to extract meaningful patterns from complex, high-dimensional biological and clinical data.
What kinds of data are expected to be analyzed?
The FOA emphasizes use of multiple data types that are already community-accessible, including:
- Genetic and genomic data (for example, variant data and other genome-scale measurements)
- Biomarker data (molecular biomarkers and related measures)
- Phenotypic information (clinical traits and other measurable characteristics tied to AD/ADRD)
Does the FOA expect applicants to create new datasets?
The description emphasizes analyzing existing, community-accessible datasets. The focus is on computational and analytic work that leverages data already available to the broader research community.
Is data integration across multiple data types encouraged?
Yes. A key emphasis is using multiple data types (genetic/genomic plus biomarker and phenotypic information) and developing analytic strategies capable of handling scale and complexity, including high-dimensional datasets.
Are generic machine learning models sufficient for this program?
The FOA indicates applicants are expected to propose thoughtful analytic strategies rather than simply applying generic models, with an emphasis on approaches that can handle complex data and produce results that are biologically interpretable and useful to the field.
What kind of output or deliverable is implied by the FOA?
The implied deliverable is stronger evidence identifying which variants matter for AD/ADRD risk or protection and how those variants relate to measurable biological or clinical features.
Is this opportunity focused on wet-lab experiments or computational analysis?
Based on the information provided, the FOA is focused on computational and analytic research, specifically AI-driven analysis of existing genetic, genomic, biomarker, and phenotypic datasets.
Are clinical trials allowed under this FOA?
No. The FOA is explicitly labeled "Clinical Trial Not Allowed", meaning the supported work should not include prospective interventional studies that meet the NIH definition of a clinical trial.
What is the activity category for this funding opportunity?
The activity category is Health.
What is the CFDA number associated with this program?
The CFDA number listed is 93.866.
Who is eligible to apply?
Eligibility is broad and includes many organization types across government, academia, nonprofit, and industry. Eligible applicants include:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments and other tribal organizations
- Public housing authorities and Indian housing authorities
- Nonprofits with 501(c)(3) status (excluding higher education institutions under those categories)
- Nonprofits without 501(c)(3) status (excluding higher education institutions under those categories)
- For-profit organizations other than small businesses
- Small businesses
- Other entities
Are minority-serving institutions specifically mentioned as eligible?
Yes. The FOA highlights additional eligible applicants including:
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
Are faith-based or community-based organizations allowed to apply?
Yes. The FOA explicitly includes faith-based or community-based organizations among eligible applicants.
Can federal agencies apply?
Yes. The FOA notes that eligible federal agencies may apply.
Are U.S. territories eligible?
Yes. The FOA includes U.S. territories or possessions as eligible applicants.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations).
What kinds of teams does this FOA seem designed to attract?
The broad eligibility suggests NIH wants multidisciplinary teams with strengths in areas such as AI/ML, genomics, and neurodegenerative disease research, including groups that may contribute unique populations, computational infrastructure, or methodological expertise.
When was this FOA created?
The FOA was created on 2019-05-06.
What is the closing date listed in the provided information?
The original closing date listed is 2022-09-07.
Does the listed closing date mean the opportunity is currently open?
The provided text notes that the date may reflect an earlier submission cycle. Based on the information provided alone, it indicates an original closing date but does not confirm current open/closed status.
Is the award ceiling or expected number of awards provided?
No. The provided information states that the exact award ceiling and number of expected awards are not listed in the text provided.
What research area does this FOA focus on?
The FOA focuses on Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD), specifically using AI-driven analysis to connect genetic variation to disease risk, protection, mechanisms, and measurable phenotypes/biomarkers.
Browse more opportunities from the same category: Health
Next opportunity: Agriculture Growing Rural Opportunities (AGRO) Activity in Ukraine
Previous opportunity: FY2019 Supplemental for National Network Grant to the National Railroad Passenger Corporation
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 19 269
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 19 269) also looked into and applied for these:
| Funding Opportunity |
|---|
| The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed) Apply for RFA GM 19 002 Funding Number: RFA GM 19 002 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Summer Research Training in Aging for Medical Students (T35 Clinical Trial Not Allowed) Apply for RFA AG 20 008 Funding Number: RFA AG 20 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pragmatic Trials of Managing Multimorbidity in Alzheimer's Disease (R61/R33 Clinical Trial Required) Apply for RFA AG 20 029 Funding Number: RFA AG 20 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54 Clinical Trial Not Allowed) Apply for RFA NS 19 019 Funding Number: RFA NS 19 019 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance Apply for GH BAA 2018 ADDENDUM02 Funding Number: GH BAA 2018 ADDENDUM02 Agency: Agency for International Development Category: Health Funding Amount: $40,000,000 |
| NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) Apply for PAR 19 281 Funding Number: PAR 19 281 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not Allowed) Apply for RFA RM 19 004 Funding Number: RFA RM 19 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Innovations in Malaria Vaccine Development (IMV) Apply for GH BAA 2018 ADDENDUM03 Funding Number: GH BAA 2018 ADDENDUM03 Agency: Agency for International Development Category: Health Funding Amount: $35,500,000 |
| Postdoctoral Research Associate Training (PRAT) Program (Fi2) Apply for PAR 19 286 Funding Number: PAR 19 286 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not Allowed) Apply for RFA TR 19 020 Funding Number: RFA TR 19 020 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Enhanced Diversity Clinical Sites (U01 Clinical Trial Required) Apply for RFA HG 19 014 Funding Number: RFA HG 19 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement to Support Navigators in Federally-facilitated Exchanges Apply for CA NAV 19 001 Funding Number: CA NAV 19 001 Agency: CMS-Consumer Information Insurance Oversight Category: Health Funding Amount: Case Dependent |
| The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required) Apply for RFA HG 19 015 Funding Number: RFA HG 19 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIA Genome Center for Alzheimer's Disease (U54 Clinical Trial Not Allowed) Apply for PAR 19 288 Funding Number: PAR 19 288 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Senescence in Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 025 Funding Number: RFA AG 20 025 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) Apply for PAR 19 289 Funding Number: PAR 19 289 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Adolescent Health and Well-Being in Urban Areas Apply for BAA NIGERIA HPNIAH 2019 Funding Number: BAA NIGERIA HPNIAH 2019 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed) Apply for RFA AI 19 042 Funding Number: RFA AI 19 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed) Apply for RFA AI 19 043 Funding Number: RFA AI 19 043 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Oscillatory Patterns of Gene Expression in Aging and Alzheimers Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 040 Funding Number: RFA AG 20 040 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 19 269", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.